Price
Target price
-
-
-
-
-
?12.92
WKN: A1W77U / Symbol: KPTI / Name: Karyopharm / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Karyopharm Therapeutics Inc. Stock
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Karyopharm Therapeutics Inc..
Based on the current price of 0.54 € the target price of 12 € shows a potential of 2117.29% for Karyopharm Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Karyopharm Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 0.060% | -21.613% | 16.277% | -56.070% | -26.257% | -36.318% | -94.599% |
| Evolus Inc | -0.700% | 1.236% | 48.516% | -39.598% | -0.807% | -41.239% | -19.911% |
| Rhythm Pharmaceuticals | -1.860% | -6.098% | 4.762% | 54.000% | -17.647% | 413.333% | 347.674% |
Comments
Karyopharm Therapeutics (KPTI) had its price target raised by HC Wainwright from $8.00 to $13.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $16.00 price target on the stock, up from $8.00.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $8.00 price target on the stock, down from $12.00.
Show more
Ratings data for KPTI provided by MarketBeat
News
Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in
